314 related articles for article (PubMed ID: 28422791)
21. Breadth of HIV-1 Env-specific antibody-dependent cellular cytotoxicity: relevance to global HIV vaccine design.
Madhavi V; Wren LH; Center RJ; Gonelli C; Winnall WR; Parsons MS; Kramski M; Kent SJ; Stratov I
AIDS; 2014 Aug; 28(13):1859-70. PubMed ID: 24937308
[TBL] [Abstract][Full Text] [Related]
22. Incorporation of Ebola glycoprotein into HIV particles facilitates dendritic cell and macrophage targeting and enhances HIV-specific immune responses.
Ao Z; Wang L; Mendoza EJ; Cheng K; Zhu W; Cohen EA; Fowke K; Qiu X; Kobinger G; Yao X
PLoS One; 2019; 14(5):e0216949. PubMed ID: 31100082
[TBL] [Abstract][Full Text] [Related]
23. Achieving Potent Autologous Neutralizing Antibody Responses against Tier 2 HIV-1 Viruses by Strategic Selection of Envelope Immunogens.
Hessell AJ; Malherbe DC; Pissani F; McBurney S; Krebs SJ; Gomes M; Pandey S; Sutton WF; Burwitz BJ; Gray M; Robins H; Park BS; Sacha JB; LaBranche CC; Fuller DH; Montefiori DC; Stamatatos L; Sather DN; Haigwood NL
J Immunol; 2016 Apr; 196(7):3064-78. PubMed ID: 26944928
[TBL] [Abstract][Full Text] [Related]
24. HIV-1 Antibody Neutralization Breadth Is Associated with Enhanced HIV-Specific CD4+ T Cell Responses.
Ranasinghe S; Soghoian DZ; Lindqvist M; Ghebremichael M; Donaghey F; Carrington M; Seaman MS; Kaufmann DE; Walker BD; Porichis F
J Virol; 2015 Dec; 90(5):2208-20. PubMed ID: 26656715
[TBL] [Abstract][Full Text] [Related]
25. Comparison of Immunogenicity in Rhesus Macaques of Transmitted-Founder, HIV-1 Group M Consensus, and Trivalent Mosaic Envelope Vaccines Formulated as a DNA Prime, NYVAC, and Envelope Protein Boost.
Hulot SL; Korber B; Giorgi EE; Vandergrift N; Saunders KO; Balachandran H; Mach LV; Lifton MA; Pantaleo G; Tartaglia J; Phogat S; Jacobs B; Kibler K; Perdiguero B; Gomez CE; Esteban M; Rosati M; Felber BK; Pavlakis GN; Parks R; Lloyd K; Sutherland L; Scearce R; Letvin NL; Seaman MS; Alam SM; Montefiori D; Liao HX; Haynes BF; Santra S
J Virol; 2015 Jun; 89(12):6462-80. PubMed ID: 25855741
[TBL] [Abstract][Full Text] [Related]
26. Toll-like receptor 3 adjuvant in combination with virus-like particles elicit a humoral response against HIV.
Poteet E; Lewis P; Chen C; Ho SO; Do T; Chiang S; Labranche C; Montefiori D; Fujii G; Yao Q
Vaccine; 2016 Nov; 34(48):5886-5894. PubMed ID: 27997339
[TBL] [Abstract][Full Text] [Related]
27. Conjugation of an scFab domain to the oligomeric HIV envelope protein for use in immune targeting.
King HAD; Gonelli CA; Tullett KM; Lahoud MH; Purcell DFJ; Drummer HE; Poumbourios P; Center RJ
PLoS One; 2019; 14(8):e0220986. PubMed ID: 31430333
[TBL] [Abstract][Full Text] [Related]
28. Env-2dCD4 S60C complexes act as super immunogens and elicit potent, broadly neutralizing antibodies against clinically relevant human immunodeficiency virus type 1 (HIV-1).
Killick MA; Grant ML; Cerutti NM; Capovilla A; Papathanasopoulos MA
Vaccine; 2015 Nov; 33(46):6298-306. PubMed ID: 26432912
[TBL] [Abstract][Full Text] [Related]
29. Stabilized HIV-1 envelope glycoprotein trimers for vaccine use.
Medina-Ramírez M; Sanders RW; Sattentau QJ
Curr Opin HIV AIDS; 2017 May; 12(3):241-249. PubMed ID: 28422788
[TBL] [Abstract][Full Text] [Related]
30. Modulation of immune responses to liposomal vaccines by intrastructural help.
Damm D; Suleiman E; Wagner JT; Klessing S; Pfister F; Elsayed H; Walkenfort B; Stobrawe J; Mayer J; Lehner E; Müller-Schmucker SM; Hasenberg M; Wyatt RT; Vorauer-Uhl K; Temchura V; Überla K
Eur J Pharm Biopharm; 2023 Nov; 192():112-125. PubMed ID: 37797679
[TBL] [Abstract][Full Text] [Related]
31. HIV-1 virus-like particles produced by stably transfected Drosophila S2 cells: a desirable vaccine component.
Yang L; Song Y; Li X; Huang X; Liu J; Ding H; Zhu P; Zhou P
J Virol; 2012 Jul; 86(14):7662-76. PubMed ID: 22553333
[TBL] [Abstract][Full Text] [Related]
32. Cross-reactivity of HIV vaccine responses and the microbiome.
Williams WB; Han Q; Haynes BF
Curr Opin HIV AIDS; 2018 Jan; 13(1):9-14. PubMed ID: 29035947
[TBL] [Abstract][Full Text] [Related]
33. TLR-9 agonist and CD40-targeting vaccination induces HIV-1 envelope-specific B cells with a diversified immunoglobulin repertoire in humanized mice.
Godot V; Tcherakian C; Gil L; Cervera-Marzal I; Li G; Cheng L; Ortonne N; Lelièvre JD; Pantaleo G; Fenwick C; Centlivre M; Mouquet H; Cardinaud S; Zurawski SM; Zurawski G; Milpied P; Su L; Lévy Y
PLoS Pathog; 2020 Nov; 16(11):e1009025. PubMed ID: 33253297
[TBL] [Abstract][Full Text] [Related]
34. Immunogenicity of RNA Replicons Encoding HIV Env Immunogens Designed for Self-Assembly into Nanoparticles.
Melo M; Porter E; Zhang Y; Silva M; Li N; Dobosh B; Liguori A; Skog P; Landais E; Menis S; Sok D; Nemazee D; Schief WR; Weiss R; Irvine DJ
Mol Ther; 2019 Dec; 27(12):2080-2090. PubMed ID: 31515132
[TBL] [Abstract][Full Text] [Related]
35. [Requirements for the Induction of Broadly Neutralizing Antibodies against HIV-1 by Vaccination].
Vzorov AN; Uryvaev LV
Mol Biol (Mosk); 2017; 51(6):945-957. PubMed ID: 29271959
[TBL] [Abstract][Full Text] [Related]
36. [A novel immunization strategy to induce strong humoral responses against HIV-1 using combined DNA, recombinant vaccinia virus and protein vaccines].
Liu C; Wang SH; Ren L; Hao YL; Zhang QC; Liu Y
Bing Du Xue Bao; 2014 Nov; 30(6):645-51. PubMed ID: 25868279
[TBL] [Abstract][Full Text] [Related]
37. Structural characteristics correlate with immune responses induced by HIV envelope glycoprotein vaccines.
Sharma VA; Kan E; Sun Y; Lian Y; Cisto J; Frasca V; Hilt S; Stamatatos L; Donnelly JJ; Ulmer JB; Barnett SW; Srivastava IK
Virology; 2006 Aug; 352(1):131-44. PubMed ID: 21894641
[TBL] [Abstract][Full Text] [Related]
38. Conformational Epitope-Specific Broadly Neutralizing Plasma Antibodies Obtained from an HIV-1 Clade C-Infected Elite Neutralizer Mediate Autologous Virus Escape through Mutations in the V1 Loop.
Patil S; Kumar R; Deshpande S; Samal S; Shrivastava T; Boliar S; Bansal M; Chaudhary NK; Srikrishnan AK; Murugavel KG; Solomon S; Simek M; Koff WC; Goyal R; Chakrabarti BK; Bhattacharya J
J Virol; 2016 Jan; 90(7):3446-57. PubMed ID: 26763999
[TBL] [Abstract][Full Text] [Related]
39. Comparison of vaccine strategies using recombinant env-gag-pol MVA with or without an oligomeric Env protein boost in the SHIV rhesus macaque model.
Earl PL; Wyatt LS; Montefiori DC; Bilska M; Woodward R; Markham PD; Malley JD; Vogel TU; Allen TM; Watkins DI; Miller N; Moss B
Virology; 2002 Mar; 294(2):270-81. PubMed ID: 12009868
[TBL] [Abstract][Full Text] [Related]
40. Harnessing Activin A Adjuvanticity to Promote Antibody Responses to BG505 HIV Envelope Trimers.
Carnathan DG; Kaushik K; Ellebedy AH; Enemuo CA; Gebru EH; Dhadvai P; Rasheed MAU; Pauthner MG; Ozorowski G; Ahmed R; Burton DR; Ward AB; Silvestri G; Crotty S; Locci M
Front Immunol; 2020; 11():1213. PubMed ID: 32612608
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
